Ipsen Withdraws Drug from Market After Potential Risks Outweigh Benefits
Ipsen announces the voluntary and immediate withdrawal of Tazverik (tazemetostat) from all markets where it is sold, across all indications. This decision follows emerging data from the SYMPHONY-1 phase Ib/III trial, which revealed a less favorable safety profile than expected.
The Independent Data Monitoring Committee (IDMC) of the SYMPHONY-1 trial indicated that, based on adverse events related to secondary hematologic malignancies, the risks could outweigh the potential benefits for patients in the therapeutic regimen evaluating tazemetostat in combination with lenalidomide and rituximab (R²) compared to R² alone in follicular lymphoma. The withdrawal affects both follicular lymphoma (FL) and epithelioid sarcoma (ES). Tazverik had received accelerated approval from the U.S. FDA in 2020 for these two indications.
Immediate Actions Taken in Clinical Trials
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Ipsen has taken immediate action to discontinue treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial. All participants will receive the standard treatment, namely lenalidomide plus rituximab only. The study will remain open, without new inclusions, to continue long-term safety follow-up of all participants. Ipsen is also discontinuing all active clinical trials and expanded access programs involving tazemetostat. The company is collaborating with the U.S. FDA to determine the next steps for the withdrawal and to provide all necessary information to finalize this process.
Financial Outlook Remains Unchanged
Ipsen states that the withdrawal should not impact the company's financial forecasts.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
